Redefining Initial Rheumatoid Arthritis Treatment: Tofacitinib Outperforms Methotrexate in Disease Control - An Open-Label Randomised Controlled Trial - PubMed
3 hours ago
- #Clinical Trial
- #Tofacitinib
- #Rheumatoid Arthritis
- Tofacitinib monotherapy showed significantly higher clinical improvement rates at 3 months (94.1%) compared to methotrexate with glucocorticoid bridging (75%) in DMARDs-naïve rheumatoid arthritis patients.
- Reductions in disease activity scores (SDAI, CDAI, DAS28-CRP, DAS28-ESR) were significantly greater with tofacitinib than methotrexate at month 3.
- Safety profiles were similar between both treatment groups.
- Tofacitinib exhibited superior cost-effectiveness compared to methotrexate combined with betamethasone.
- Findings support tofacitinib as a potential first-line bridging option for initial rheumatoid arthritis treatment due to early efficacy, comparable safety, and better cost-effectiveness.